banner
EGFR-HER2 inhibitor WHI-P 154, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ429

EGFR-HER2 inhibitor WHI-P 154, Purity ≥98%

Synonym: WHI-P154; 211555-04-3; WHI-P 154; jak3 inhibitor ii; 2-Bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; 2-Bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol; 2-Bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol; EGFR-HER2 inhibitor

  • MDL: MFCD02179366
  • CAS Number: 211555-04-3
  • Compound CID: 3795
img
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
WHI-P 154, soluble in DMSO and insoluble in ethanol and water, is a potent and specific inhibitor of the tyrosine kinase activity of EGFR. It targets EGFR, JAK3, Src, and VEGFR.
Molecular Weight
376.2
Molecular Formula
C16H14BrN3O3
Targets
EGFR: 4 nM; JAK3: 1.8 nM; Src: 100 nM; VEGFR: 100 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 74 mg/mL (196.7 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
WHI-P 154 can be used to study JAK3 inhibition in the context of immune response modulation.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0